Firazyr advisory committee canceled
Executive Summary
Jerini's hereditary angiodema treatment Firazyr (icatibant) will not undergo a review by FDA's Pulmonary-Allergy Drugs Advisory Committee, the firm says Jan. 8. The panel was scheduled to meet Feb. 20 to discuss the orphan drug candidate, which has an April 26 user fee date under priority review...
You may also be interested in...
To Meet Or Not To Meet? That Is CDER’s Question As Cmte. Cancellations Rise
Clinical development and regulatory review are already full of uncertainties, but this year FDA introduced a new twist - canceling and postponing advisory committee meetings. Almost half of the scheduled meetings have not taken place, which may or may not be a bad sign for industry
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.